Researchers at the Fred Hutchinson Cancer Research Center and the University of Washington say a new study suggests ways to improve immune therapy for certain cancers including a virus-associated form of Merkel cell carcinoma, a rare, aggressive skin cancer.
FDA approved an Investigational Device Exemption application to initiate a multi-center study for the treatment of recurrent cutaneous squamous cell carcinoma in immunocompromised patients using the Alpha DaRT.
